SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Inhibition of G-protein signalling in cardiac dysfunction of intellectual developmental disorder with cardiac arrhythmia (IDDCA) syndrome.

De Nittis, P; Efthymiou, S; Sarre, A; Guex, N; Chrast, J; Putoux, A; Sultan, T; Raza Alvi, J; Ur Rahman, Z; Zafar, F; et al. De Nittis, P; Efthymiou, S; Sarre, A; Guex, N; Chrast, J; Putoux, A; Sultan, T; Raza Alvi, J; Ur Rahman, Z; Zafar, F; Rana, N; Rahman, F; Anwar, N; Maqbool, S; Zaki, MS; Gleeson, JG; Murphy, D; Galehdari, H; Shariati, G; Mazaheri, N; Sedaghat, A; SYNAPS Study Group; Lesca, G; Chatron, N; Salpietro, V; Christoforou, M; Houlden, H; Simonds, WF; Pedrazzini, T; Maroofian, R; Reymond, A (2021) Inhibition of G-protein signalling in cardiac dysfunction of intellectual developmental disorder with cardiac arrhythmia (IDDCA) syndrome. J Med Genet, 58 (12). pp. 815-831. ISSN 1468-6244 https://doi.org/10.1136/jmedgenet-2020-107015
SGUL Authors: Maroofian, Reza

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (13MB) | Preview

Abstract

BACKGROUND: Pathogenic variants of GNB5 encoding the β5 subunit of the guanine nucleotide-binding protein cause IDDCA syndrome, an autosomal recessive neurodevelopmental disorder associated with cognitive disability and cardiac arrhythmia, particularly severe bradycardia. METHODS: We used echocardiography and telemetric ECG recordings to investigate consequences of Gnb5 loss in mouse. RESULTS: We delineated a key role of Gnb5 in heart sinus conduction and showed that Gnb5-inhibitory signalling is essential for parasympathetic control of heart rate (HR) and maintenance of the sympathovagal balance. Gnb5-/- mice were smaller and had a smaller heart than Gnb5+/+ and Gnb5+/- , but exhibited better cardiac function. Lower autonomic nervous system modulation through diminished parasympathetic control and greater sympathetic regulation resulted in a higher baseline HR in Gnb5-/- mice. In contrast, Gnb5-/- mice exhibited profound bradycardia on treatment with carbachol, while sympathetic modulation of the cardiac stimulation was not altered. Concordantly, transcriptome study pinpointed altered expression of genes involved in cardiac muscle contractility in atria and ventricles of knocked-out mice. Homozygous Gnb5 loss resulted in significantly higher frequencies of sinus arrhythmias. Moreover, we described 13 affected individuals, increasing the IDDCA cohort to 44 patients. CONCLUSIONS: Our data demonstrate that loss of negative regulation of the inhibitory G-protein signalling causes HR perturbations in Gnb5-/- mice, an effect mainly driven by impaired parasympathetic activity. We anticipate that unravelling the mechanism of Gnb5 signalling in the autonomic control of the heart will pave the way for future drug screening.

Item Type: Article
Additional Information: © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Keywords: GNB5variants, Gnb5-null mouse models, IDDCA, cardiac conduction anomalies, SYNAPS Study Group, Genetics & Heredity, 06 Biological Sciences, 11 Medical and Health Sciences
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: J Med Genet
ISSN: 1468-6244
Language: eng
Dates:
DateEvent
22 November 2021Published
10 November 2020Published Online
4 September 2020Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
31003A_182632Swiss National Science Foundationhttp://dx.doi.org/10.13039/501100001711
MR/S01165X/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MR/S005021/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
G0601943Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
WT093205 MAWellcome Trusthttp://dx.doi.org/10.13039/100004440
WT104033AIAWellcome Trusthttp://dx.doi.org/10.13039/100004440
PubMed ID: 33172956
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/112612
Publisher's version: https://doi.org/10.1136/jmedgenet-2020-107015

Actions (login required)

Edit Item Edit Item